Abstract
Letters2 March 2010Cost-Effectiveness of Biologics in Early Rheumatoid ArthritisMaarten Boers, MSc, MD, PhDMaarten Boers, MSc, MD, PhDFrom VU University Medical Center, 1007 MB, Amsterdam, the Netherlands.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-152-5-201003020-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:I think the authors and I agree on most of the issues, but we differ in the wording of our conclusions. It is wise to avoid firm conclusions in the face of shaky evidence. A model can never fully replace reality, and we probably need another 10 years of additional experience with biologics to be fully certain of their cost-effectiveness. Nevertheless, when we trust the model, and it points unmistakably in 1 direction, we shouldn't be afraid to clearly communicate what it shows. This is especially important in the area of biologics in rheumatoid arthritis, where intense marketing ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
